Takeda Balks At Covering Lilly's $3 Billion Share Of U.S. Jury Actos Verdict
This article was originally published in PharmAsia News
Executive Summary
Takeda Pharmaceutical informed Eli Lilly it might have to shoulder the $3 billion in punitive damages assessed against it by a jury in a U.S. court suit over its diabetes drug Actos (pioglitazone).